StockData
Kiniksa Pharmaceuticals International, plc logo

Kiniksa Pharmaceuticals International, plc (KNSA) stock

KNSANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 27, 2026Score 14/30469% above fair value
$95.05−0.06 (-0.06%)

Close on Nov 18, 2026Market cap $14.94BP/E 73.1Yield –

Kiniksa Pharmaceuticals International operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kiniksa Pharmaceuticals International's operating income for the twelve months ending Sep 30, 2026 was $130.47M, up 241.9% year over year. For fiscal 2025 it was $77.22M. The highest annual figure on record is $77.22M in fiscal 2025.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025$77.22M–
FY2024Dec 31, 2024-$45.62M–
FY2023Dec 31, 2023-$25.20M-357.8%
FY2022Dec 31, 2022$9.77M–
FY2021Dec 31, 2021-$156.64M–
FY2020Dec 31, 2020-$157.36M–
FY2019Dec 31, 2019-$169.96M–
FY2018Dec 31, 2018-$108.16M–
FY2017Dec 31, 2017-$65.40M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$54.24M+125.8%
Q2 FY2026Jun 30, 2026$27.19M+34.9%
Q1 FY2026Mar 31, 2026$29.27M+120.5%
Q4 FY2025Dec 31, 2025$19.77M–
Q3 FY2025Sep 30, 2025$24.02M–
Q2 FY2025Jun 30, 2025$20.16M–
Q1 FY2025Mar 31, 2025$13.27M–
Q4 FY2024Dec 31, 2024-$19.30M-23925.9%
Q3 FY2024Sep 30, 2024-$9.66M–
Q2 FY2024Jun 30, 2024-$117.00K–
Q1 FY2024Mar 31, 2024-$16.54M–
Q4 FY2023Dec 31, 2023$81.00K-98.7%
Q3 FY2023Sep 30, 2023-$10.93M-123.5%
Q2 FY2023Jun 30, 2023-$3.15M–
Q1 FY2023Mar 31, 2023-$11.20M–
Q4 FY2022Dec 31, 2022$6.05M–
Q3 FY2022Sep 30, 2022$46.41M–
Q2 FY2022Jun 30, 2022-$19.37M–
Q1 FY2022Mar 31, 2022-$23.32M–
Q4 FY2021Dec 31, 2021-$36.13M–
Q3 FY2021Sep 30, 2021-$30.67M–
Q2 FY2021Jun 30, 2021-$40.56M–
Q1 FY2021Mar 31, 2021-$49.28M–
Q4 FY2020Dec 31, 2020-$52.90M–
Q3 FY2020Sep 30, 2020-$43.22M–
Q2 FY2020Jun 30, 2020-$31.86M–
Q1 FY2020Mar 31, 2020-$29.39M–
Q4 FY2019Dec 31, 2019-$32.58M–
Q3 FY2019Sep 30, 2019-$30.45M–
Q2 FY2019Jun 30, 2019-$39.29M–
Q1 FY2019Mar 31, 2019-$67.65M–
Q4 FY2018Dec 31, 2018-$44.14M–
Q3 FY2018Sep 30, 2018-$26.16M–
Q2 FY2018Jun 30, 2018-$21.53M–
Q1 FY2018Mar 31, 2018-$16.34M–
Q4 FY2017Dec 31, 2017-$32.71M–
Q3 FY2017Sep 30, 2017-$16.25M–
Q2 FY2017Jun 30, 2017-$11.39M–

More Kiniksa Pharmaceuticals International figures

See a number that looks wrong?